Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study

Kuo Chin Chiu, Yen Li Chou, Jeng Yuan Hsu, Ming Shian Lin, Ching Hsiung Lin, Pai Chien Chou, Chun Liang Chou, Chun Hua Wang, Han Pin Kuo

研究成果: 雜誌貢獻文章

8 引文 (Scopus)

摘要

BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.
原文英語
文章編號14010
期刊npj Primary Care Respiratory Medicine
24
DOIs
出版狀態已發佈 - 五月 20 2014
對外發佈Yes

指紋

Budesonide
Asthma
Forced Expiratory Volume
Adrenal Cortex Hormones
Therapeutics
Physicians
ciclesonide
Pharmaceutical Preparations
Inhalation
Anti-Inflammatory Agents
Lung

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

引用此文

Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy : A randomised parallel-group study. / Chiu, Kuo Chin; Chou, Yen Li; Hsu, Jeng Yuan; Lin, Ming Shian; Lin, Ching Hsiung; Chou, Pai Chien; Chou, Chun Liang; Wang, Chun Hua; Kuo, Han Pin.

於: npj Primary Care Respiratory Medicine, 卷 24, 14010, 20.05.2014.

研究成果: 雜誌貢獻文章

@article{1de9c32b07bd478abdfd539cb92557ac,
title = "Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: A randomised parallel-group study",
abstract = "BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0{\%} vs. 58.7{\%}, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.",
author = "Chiu, {Kuo Chin} and Chou, {Yen Li} and Hsu, {Jeng Yuan} and Lin, {Ming Shian} and Lin, {Ching Hsiung} and Chou, {Pai Chien} and Chou, {Chun Liang} and Wang, {Chun Hua} and Kuo, {Han Pin}",
year = "2014",
month = "5",
day = "20",
doi = "10.1038/npjpcrm.2014.10",
language = "English",
volume = "24",
journal = "npj Primary Care Respiratory Medicine",
issn = "2055-1010",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy

T2 - A randomised parallel-group study

AU - Chiu, Kuo Chin

AU - Chou, Yen Li

AU - Hsu, Jeng Yuan

AU - Lin, Ming Shian

AU - Lin, Ching Hsiung

AU - Chou, Pai Chien

AU - Chou, Chun Liang

AU - Wang, Chun Hua

AU - Kuo, Han Pin

PY - 2014/5/20

Y1 - 2014/5/20

N2 - BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.

AB - BACKGROUND: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. AIMS: This study aimed to compare the clinical benefit of CIC with budesonide (BUD) in step-down therapy. METHODS: A total of 150 patients with mild-to-moderate asthma well controlled by a combination of ICS and long-acting β2-agonist were randomised to receive either CIC 320 μg (n = 75) once daily or 2 inhalations of BUD 200 μg (n = 75) twice daily for 12 weeks. The forced expiratory volume in 1 s (FEV1), maximum mid-expiratory flow (MMEF) and asthma control test (ACT) scores were measured. Ranked stratification of patients and physicians was assessed. RESULTS: Drug adherence was significantly higher in the CIC group than in the BUD group (76.0% vs. 58.7%, P = 0.03). The FEV1 and MMEF remained stable throughout the 12-week CIC treatment. In the BUD group, FEV1 significantly decreased at weeks 4 and 12. MMEF had a higher value in the CIC group than in the BUD group. Both patients and physicians ranked CIC over BUD. CONCLUSIONS: CIC is more effective and has better drug adherence than BUD as step-down treatment when asthma is well controlled by combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=84904396631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904396631&partnerID=8YFLogxK

U2 - 10.1038/npjpcrm.2014.10

DO - 10.1038/npjpcrm.2014.10

M3 - Article

C2 - 24841163

AN - SCOPUS:84904396631

VL - 24

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

SN - 2055-1010

M1 - 14010

ER -